SlideShare a Scribd company logo
1 of 90
Download to read offline
Ε. ΑΝΔΡΙΩΤΗΣ
Νεώτερα δεδομζνα ςτην ακτινοθεραπεία του
καρκίνου του προςτάτη
2ο Συμπόσιο Κλινικής Ογκολογίας Ρόδου
Ακτινοθεραπευτήσ Ογκολόγοσ
Euromedica – Αθήναιον Α & Ιατρικό Κζντρο Αθηνών
Cancer Cases in 2013
Cancer Deaths in 2013
ΚΙΝΔΥΝΟΣ ΕΜΦΑΝΙΣΗΣ
Male Cancer Mortality Rates 1930 to 2009
prostate
colorectal
stomach
lung
CaPSURE: Risk Category at
Diagnosis
0
20
40
60
80
100
1989 1990 1991 1992 1993 1994 1995 1996 1997 1999 2000 2001 2002
Patients(%)
High risk
Intermediate risk
Low risk
30.2%
37.3%
32.5%
25.1%
38.5%
36.4%
16.0%
37.2%
46.8%
36.6%
33.8%
29.5%
Reprinted with permission from Cooperberg MR et al. J Urol. 2003;170:S21
Treating prostate cancer
Surgery?
Radiation?
Or Watchful Waiting?
Καηεςθύνζειρ για ηην θεπαπεία ηοπικήρ νόζος
Ιαηπικά πποβλήμαηα αζθενούρ Νοζηπόηηηα Ca πποζηάηος
Πποζδόκιμο επιβίυζηρ (αναμενόμενη)
• Δνδοκατική νόζορ (Σ1/Σ2), Gleason score (< 7) & PSA(<10)
- Ρηδηθή πξνζηαηεθηνκή ή αθηηλνζεξαπεία ή παξαθνινύζεζε
• Σοπικά πποσυπημένη νόζορ (Σ3/Σ4)
– Αθηηλνζεξαπεία + Οξκνληθόο απνθιεηζκόο (LHRH αλάινγα)
bRFS in pts with favorable tumors
(T1-T2A, bGS< 6, iPSA< 10 ng/ml)
Kupelian PA, JCO 2002
bRFS in pts with unfavorable tumors
(T2b-T2c, bGS> 6, iPSA>10 ng/ml)
Kupelian PA, JCO 2002
Long-Term Functional Outcomes after
Treatment for Localized Prostate Cancer
The Prostate Cancer Outcomes Study (PCOS), comprised 1655 men in
whom localized prostate cancer had been diagnosed between the ages of
55 and 74 years and who had undergone either surgery (1164 men) or
radiotherapy (491 men).
Functional status was assessed at baseline and at 2, 5, and 15 years after
diagnosis
• Urinary Incontinence: worse with surgery at 2 and 5 years
but the same by 15 years
• Erectile Dysfunction: worse with surgery at 2 and 5 years
but the same by 15 years
• Bowel Urgency: worse with radiation at 2 and 5 years' but
by 15 years' the same
N Engl J Med 2013; 368:436-445
Η ΑΚΘ ΒΔΛΣΙΩΝΔΙ
ΣΗΝ ΔΠΙΒΙΩ΢Η;
ΝΑΙ !
Η ΑΚΘ βειηηώλεη ηελ 10-εηή επηβίσζε
Warde P et all Lancet 2011
Widmark A et all Lancet 2009
Vakalis  - RT for prostate cancer
Vakalis  - RT for prostate cancer
Vakalis  - RT for prostate cancer
Vakalis  - RT for prostate cancer
Vakalis  - RT for prostate cancer
Vakalis  - RT for prostate cancer
ΣΟΠΙΚΗ ΤΠΟΣΡΟΠΗ – ΓΟ΢Η ΑΚΣΙΝΟΘΔΡΑΠΔΙΑ΢
Vakalis  - RT for prostate cancer
Χακειή δόζε
ηο ππόβλημα λύνεηαι
με
Αύξηζη ηηρ δόζηρ
Σςσαιοποιημένερ μελέηερ πος δείσνοςν ηο όθελορ από ηην
αύξηζη ηηρ δόζηρ (συπίρ IMRT και οπμονοθεπαπεία)
RCT N Comparison Result
Pollack
(MDA)
2007 update
301 70Gy/35 vs. 78Gy/39 59% vs. 78% bPFS at
5 years
Zietman
2005
393 70.2Gy vs. 79.2Gy (proton boost) 61% vs. 80% bPFS at
5 years
Peeters
(Dutch)
2006
664 68Gy/34 vs. 78Gy/39 54% vs. 64% FFF at 5
years
Dearnaley
(RTO1)
2007
843 64Gy/32 vs. 74Gy/37 60% vs. 71% bPFS at
5 years
Hoskin
(Mt Vernon)
2007
220 55Gy/20 vs. 35.75Gy/13 + HDR 8.5Gy x 2 64% vs. 80% bPFS at
5 years
bPFS=biochemical progression free survival FFF= freedom from failure
Low Risk
T1-2, GS ≤6, PSA ≤10
Memorial Sloan Kettering Cancer Center
IMRT Dose Escalation
Zelefsky MJ, Chan H, et. Al. Journal of Urology Vol. 176, 1415-1419, Oct 2006
Intermediate Risk
Memorial Sloan Kettering Cancer Center
IMRT Dose Escalation
Zelefsky MJ, Chan H, et. Al. Journal of Urology Vol. 176, 1415-1419, Oct 2006
T1-2, GS 6, PSA > 10
T1-2, GS >6, PSA  10
T3, GS  6, PSA  10
High Risk
GS >6, PSA >10
Memorial Sloan Kettering Cancer Center
IMRT Dose Escalation
Zelefsky MJ, Chan H, et. Al. Journal of Urology Vol. 176, 1415-1419, Oct 2006
Improving the Results of Radiotherapy
Dose escalation– increasing the dose of
radiation by 10% can increase local control
by 20% (level 1 evidence)
3D Conformal, IMRT, HDR Brachytherapy boost
Combination treatment with radiotherapy and
androgen suppression
Vakalis  - RT for prostate cancer
Αύξηζη ηηρ δόζηρ – Σοξικόηηηα
Απώηεπη Σοξικόηηηα ζηιρ μεγάλερ μη-
IMRT μελέηερ αύξηζηρ ηηρ δόζηρ
Γαζηπενηεπική Σοξικόηηηα Σοξικόηηηα από Οςποποιηηικό
Grade 2 Grade 3 Grade 2 Grade 3
Κλαζζική
Γόζη
8 – 23% 1 – 2% 6 – 28% 1 – 8%
Ττηλή Γόζη
(Μη-IMRT)
7 – 30% 1 -7% 10 – 30% 1 – 15 %
2 θοπέρ μεγαλύηεπορ κίνδςνορ ζοβαπήρ ηοξικόηηηαρ !
Vakalis  - RT for prostate cancer
Evolving
Radiation
Technology
ΣΔΥΝΙΚΔ΢ ΑΚΣΙΝΟΘΔΡΑΠΔΙΑ΢
Vakalis  - RT for prostate cancer
Vakalis  - RT for prostate cancer
J Urol 2001; 166: 876
≥ Grade 2 Απώηεξε Σνμηθόηεηα από Οξζό
3D-CRT: 14%
IMRT: 2%
p= 0.005
Γαζηπενηεπική
Σοξικόηηηα
Σοξικόηηηα
Οςποποιηηικού
Grade 2 Grade 3 Grade 2 Grade 3
Κλαζζική
Γόζη
8 – 23% 1 – 2% 6 – 28% 1 – 8%
Ττηλή
Γόζη
(Μη-IMRT)
7 – 30% 1 -7% 10 – 30% 1 – 15 %
Ττηλή
Γόζη
(IMRT)
1 – 2% 0 – 3% 9 – 23% 0 – 6%
Απώηεπη Σοξικόηηηα ζηιρ IMRT μελέηερ αύξηζηρ ηηρ
δόζηρ
Κίνδςνορ ζοβαπήρ ηοξικόηηηαρ
Υαμηλή δόζη συπίρ IMRT = Ττηλή δόζη με IMRT
Vakalis  - RT for prostate cancer
Vakalis  - RT for prostate cancer
Vakalis  - RT for prostate cancer
Vakalis  - RT for prostate cancer
Vakalis  - RT for prostate cancer
Vakalis  - RT for prostate cancer
Μέηπια Τποκλαζμαηοποίηζη
8 εβδομάδερ θεπαπείαρ είναι απαπαίηηηερ;
Οι κλινικέρ μελέηερ
Vakalis  - RT for prostate cancer
Vakalis  - RT for prostate cancer
• Conventional or Hypofractionated High Dose
Intensity Modulated Radiotherapy for Prostate
Cancer
• Hypothesis: hypofractionated radiotherapy
schedules for localised prostate cancer will
improve the therapeutic ratio by either:
a) Improving tumour control
b) Reducing normal tissue side effects
CHHiP Trial
T1B - T3A N0 M0
Estimated Risk of SV involvement ≤ 30%
PSA ≤ 30ng/ml
Randomise
Group 1
74Gy / 37F
7.5 weeks
(Standard)
Group 2
60Gy / 20F
4.0 weeks
(Hypofractionation)
Group 3
57Gy / 19F
3.8 weeks
(Hypofractionation)
Trial Schema
CHHiP Trial
T1c-2a
GS <7
PSA <10
73.8 Gy/41 Fx
70 Gy/28 Fx
RTOG 0415 Schema
n=800
Endpoint is 5 Year BFFF
Non-inferiority margin 7% (Control 85%, Exp 78%)
Vakalis  - RT for prostate cancer
Vakalis  - RT for prostate cancer
Cyberknife
Vakalis  - RT for prostate cancer
SBRT
cheaper but more toxic
than IMRT
for Prostate Cancer
The study results were published online March 10 in
theJournal of Clinical Oncology.
Vakalis  - RT for prostate cancer
Vakalis  - RT for prostate cancer
CT scan is obtained at the time of the Simulation
Fiducials may be inserted
before this step. CT images are
then imported into the
treatment planning computer
bladder
Radiation zone
prostate
rectum
Goal = radiation zone precisely around
the prostate cancer with small margin
IMRT (intensity
modulated
radiation therapy)
using 7 different
beams to target the
prostate
The computer can
determine the optimal
number of beams to
deliver the radiation
dose to hit the target and
avoid other structures
Prostate
Seminal Vesicles
Courtesy: Chester Ramsey
Prostate
Seminal Vesicles
Alignment on markers Alignment on mid gland prostate
Κίνηςη του προςτάτη
AP  4.15 mm
SI  3.14 mm
RL  1.92 mm
There is significant movement of the
prostate gland based on daily gas in rectum
Planned target
Rectal gas
No Rectal gas
Planned target,
missed badly if
rectal gas pushes
the prostate
forward
Rectal balloon
After IMRT was established then IGRT
(image guided) was introduced
Vakalis  - RT for prostate cancer
Lower Risk of Side Effects with Image Guided IMRT
compared to IMRT
Is there ever a need for
radiation after a man
has already had his
prostate removed
PostOp Radiation (Adjuvant Therapy) if the
pathology report from the surgery raises the concern:
“was the cancer completely removed?”
Salvage Radiation
Οπιζμοί
• Άκεζα κεηεγρεηξεηηθή (adjuvant)
– Με αληρλεύζηκν PSA κεηεγρεηξεηηθά
– Α/ζ ζε 3-12 κήλεο (αθνύ βειηησζεί ε αθξάηεηα)
• Αθηηλνζεξαπεία δηάζσζεο (salvage)
– Αληρλεύζηκν PSA κεηεγρεηξεηηθά
– ↑ ηνπ PSA αθνύ πξώηα κεδεληζηεί
NCCN Advice on PostOp Radiation
RP (radical prostatectomy) PLND (pelvic lymph node dissection) RT (radiation
therapy) ADT (androgen deprivation therapy e.g. Lupron)
Adverse Features
1.Positive Surgical Margins
2.Invasion into the Seminal Vesicles
3.Extracapsular Extension
4.Detectable PSA (after surgery the PSA
should fall to undetectable by a few weeks)
Impact of Path Reporting Positive
Surgical Margins
Risk Group + Margins - Margins
Low risk 5.1% 0.4%
Intermediate 17% 6.5%
High 43% 21.5%
Odds of a PSA Relapse
J Urol. 2010;183(1):145.
PostOp Radiation…does it work?
SWOG 8794 Trial path (425 men) = extraprostatic extension after surgery
10 Year PSA Cure Rate (seminal vesicle)
Surgery Only 12%
Surgery Plus Radiation 36%
EORTC (1005 men)
5 Year Cure Rate if Positive Margins
Surgery Only 49%
Surgery Plus Radiation 78%
German Study (Wiegel, 268 men)
5 Year Cure Rate all T3
Surgery Only 54%
Surgery Plus Radiation 72%
Survival Benefits from PostOp
Radiation for High Risk Patients
RT RTRT
No RT No RTNo RT
Άμεζα μεηεγσειπηηική ή
α/θ διάζυζηρ;
Is it Better to Treat PostOp for High Risk
Features or to Wait and Treat later if the
PSA starts rising (salvage)?
8 Year Specific Survival by Group and Therapy
Immediate RT Delayed
Positive Margins 91% 67%
Extra-capsular Spread 92% 75%
Gleason 7 88% 72%
Node Metastases 88% 68%
Role of postoperative radiotherapy after pelvic lymphadenectomy and
radical retropubic prostatectomy: a single institute experience of 415
patients
Cozzarini. IJROBP 2004;59:674
Υπόνορ έναπξηρ ηηρ άμεζηρ α/θ
≥ 3 επειζόδια ακράηειας : ζηοσς 6 μήνες: 33%, ζηοσς 12
μήνες: 18%, ζηοσς 24-60 μήνες: 15%
΢ηα πεξηζζόηεξα θέληξα 3-12 κήλεο κεηεγρ/θά
αθνύ απνθαηαζηαζεί ε εγθξάηεηα
• Δελ θαίλεηαη λα επεξεάδεη ηελ λόζν
• Η πνιύ πξώηκε έλαξμε → ↑ ηνπ % απώηεξεο
ηνμηθόηεηαο από ην νπξνπνηεηηθό
Feng et al, IJROBP, 2005
Salvage Radiation: if months or years
after surgery the PSA blood tests
starts rising again
Salvage Radiation…does it work?
Depends…
Original Pathology
What was the Gleason?
Where the surgical margins clear?
Did the cancer involve the seminal vesicles or lymph
nodes?
Was there extra-capsular spread?
How long ago was the surgery?
How fast is the PSA rising (doubling time)?
How high the did PSA get before deciding to try
radiation?
How high a dose of radiation will be used?
http://www.mskcc.org/cancer-care/adult/prostate/prediction-tools
http://nomograms.mskcc.org/Prostate/SalvageRadiationTherapy.aspx
http://nomograms.mskcc.org/Prostate/SalvageRadiationTherapy.aspx
Does Salvage Radiation Improve Survival?
Mayo (2657) No improvement in 10 y mortality
(70% versus 69%)
Hopkins (635) Improved cancer mortality at 10
years 86% versus 62%
Duke (519) All cause mortality at 11 years was
reduced by 47%
J Urol. 2009;182(6):2708
JAMA. 2008;299(23):2760.
ΑΚΣΙΝΟΘΔΡΑΠΔΙΑ ΢ΣΟΝ ΠΡΩΙΜΟ
ΚΑΡΚΙΝΟ ΣΟΤ ΠΡΟ΢ΣΑΣΗ
• Δξυηεπική ακηινοθεπαπεία (EBRT)
– ΢ύμμοπθη ηξηζδηάζηαηε αθηηλνζεξαπεία (3 Dimensional Conformal Radiotherapy
– 3D CRT)
– Σξηζδηάζηαηε αθηηλνζεξαπεία διαμοπθούμενηρ ένηαζηρ (Intensity Modulated
Radiation Therapy – IMRT/VMAT-IGRT)
– Αθηηλνζεξαπεία κε ππυηόνια (Proton Beam Radiation Therapy)
– ΢ηεπεοηακηική αθηηλνζεξαπεία ηνπ πξνζηάηε (Stereotactic Radiotherapy)
• Βπασςθεπαπεία
– Μόληκα εκθπηεύκαηα ρακεινύ ξπζκνύ δόζεο(LDR) (seeds I-125 ή Pd-103)
– Πξνζσξηλά εκθπηεύκαηα πςεινύ ξπζκνύ δόζεο (HDR) (Iridium-192 sources)
ΔΜΦΤΣΔΤ΢Η ΚΟΚΚΩΝ
ΔΝΓΔΙΞΔΙ΢ ΒΡΑΥΤΘΔΡΑΠΔΙΑ΢
ΣΟΤ ΠΡΟ΢ΣΑΣΗ (LDR)
RECOMMENDED OPTIONAL INVESTIGATIONAL
Do well Fair Do poorly
PSA (ng/ml) <10 10-20 >20
Gleason Score 5-6 7 8-10
Stage T1c - T2a T2b - T2c T3
IPSS 0 - 8 9 - 19 >20
Prostate Volume (g) <40 40 - 60 >60
Q max mls/sec >15 15 - 10 <10
Residual Volume cc >200
TURP +/- +
ESTRO/EAU/EORTC recommendations on seed implantation for localized prostate
Cancer. Ash D et al. Radiother Oncol; 2000: 57, 315-321
HDR brachytherapy
88
HDR
Vakalis  - RT for prostate cancer
ηελεςηαίερ ζκέτειρ
Εμσηεξηθή Αθηηλνζεξαπεία αζθαιήο θαη δξαζηηθή
• βειηηώλεη ηελ επηβίσζε κε απνδεθηή ηνμηθόηεηα ζε πςεινύ θηλδύλνπ
θαη ηνπηθά πξνρσξεκέλν Ca
• αύμεζε ηεο δόζεο πξνθαιεί θαιύηεξν έιεγρν (level 1 evidence)
Σερλνινγία πνπ δηαηίζεηαη ζηελ ΑΚΘ πνιύ πξνρσξεκέλε
• απμάλεη ηε ζπλνιηθή δόζε
• ρνξεγεί πςειή δόζε αλά ζπλεδξία
• κεηώλεη ηνλ ζπλνιηθό ρξόλν ζεξαπείαο
• παξαθνινπζεί ηε θίλεζε ηνπ πξνζηάηε θη εληνπίδεη αθξηβώο ην ζηόρν
Είλαη ππεπζπλόηεηα ησλ γηαηξώλ λα γλσξίδνπλ πνηεο πεξηνρέο λα
αθηηλνβνιήζνπλ, πώο λα ζρεδηάζνπλ ηε ζεξαπεία θαη πόηε πξέπεη λα
αθηηλνβνιήζνπλ

More Related Content

What's hot

A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasEuropean School of Oncology
 
Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadj...
Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadj...Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadj...
Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadj...Egyptian National Cancer Institute
 
Cetuximab in scchn how far we go?
Cetuximab in scchn  how far we go?Cetuximab in scchn  how far we go?
Cetuximab in scchn how far we go?Mohamed Abdulla
 
Radiotherapy in hepatic, pancreatic & biliary tract cancers
Radiotherapy in hepatic, pancreatic & biliary tract cancersRadiotherapy in hepatic, pancreatic & biliary tract cancers
Radiotherapy in hepatic, pancreatic & biliary tract cancersJyotirup Goswami
 
2012-michael joiner-hypofractionation
2012-michael joiner-hypofractionation2012-michael joiner-hypofractionation
2012-michael joiner-hypofractionationfondas vakalis
 
pitutary management
pitutary management pitutary management
pitutary management PRARABDH95
 
Neoadjuvant therapy of rectal cancer
Neoadjuvant therapy of rectal cancerNeoadjuvant therapy of rectal cancer
Neoadjuvant therapy of rectal cancerMohamed Abdulla
 
COLON CANCER
COLON CANCERCOLON CANCER
COLON CANCERPAIRS WEB
 
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...Mauricio Lema
 
NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...
NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...
NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...European School of Oncology
 
Oligometastatic prostate cancer- radiation Therapy
Oligometastatic prostate cancer- radiation TherapyOligometastatic prostate cancer- radiation Therapy
Oligometastatic prostate cancer- radiation Therapykamali purushothaman
 
Hypofractionation in carcinoma prostate
Hypofractionation in carcinoma prostateHypofractionation in carcinoma prostate
Hypofractionation in carcinoma prostateNarayan Adhikari
 
( )Anal scc
( )Anal scc( )Anal scc
( )Anal sccBDU
 
Prostate cancer nemrock 2015 sanofi
Prostate cancer nemrock 2015   sanofiProstate cancer nemrock 2015   sanofi
Prostate cancer nemrock 2015 sanofiMohamed Abdulla
 
Controversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast CancerControversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast Cancerspa718
 
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...Santam Chakraborty
 

What's hot (20)

A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
 
Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadj...
Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadj...Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadj...
Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadj...
 
Cetuximab in scchn how far we go?
Cetuximab in scchn  how far we go?Cetuximab in scchn  how far we go?
Cetuximab in scchn how far we go?
 
Radiotherapy in hepatic, pancreatic & biliary tract cancers
Radiotherapy in hepatic, pancreatic & biliary tract cancersRadiotherapy in hepatic, pancreatic & biliary tract cancers
Radiotherapy in hepatic, pancreatic & biliary tract cancers
 
2012-michael joiner-hypofractionation
2012-michael joiner-hypofractionation2012-michael joiner-hypofractionation
2012-michael joiner-hypofractionation
 
Rectal Cancer
Rectal Cancer Rectal Cancer
Rectal Cancer
 
pitutary management
pitutary management pitutary management
pitutary management
 
Targetted agents in head and neck cancers
Targetted agents in head and neck cancersTargetted agents in head and neck cancers
Targetted agents in head and neck cancers
 
Neoadjuvant therapy of rectal cancer
Neoadjuvant therapy of rectal cancerNeoadjuvant therapy of rectal cancer
Neoadjuvant therapy of rectal cancer
 
COLON CANCER
COLON CANCERCOLON CANCER
COLON CANCER
 
IO en NSCLC
IO en NSCLCIO en NSCLC
IO en NSCLC
 
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
 
NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...
NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...
NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...
 
Oligometastatic prostate cancer- radiation Therapy
Oligometastatic prostate cancer- radiation TherapyOligometastatic prostate cancer- radiation Therapy
Oligometastatic prostate cancer- radiation Therapy
 
Oligo final
Oligo finalOligo final
Oligo final
 
Hypofractionation in carcinoma prostate
Hypofractionation in carcinoma prostateHypofractionation in carcinoma prostate
Hypofractionation in carcinoma prostate
 
( )Anal scc
( )Anal scc( )Anal scc
( )Anal scc
 
Prostate cancer nemrock 2015 sanofi
Prostate cancer nemrock 2015   sanofiProstate cancer nemrock 2015   sanofi
Prostate cancer nemrock 2015 sanofi
 
Controversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast CancerControversies in Surgical Approach to Breast Cancer
Controversies in Surgical Approach to Breast Cancer
 
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...
 

Viewers also liked

HER2 negative metastatic breast ca
HER2 negative metastatic breast caHER2 negative metastatic breast ca
HER2 negative metastatic breast cafondas vakalis
 
Palliative Radiotherapy Vakalis
Palliative Radiotherapy VakalisPalliative Radiotherapy Vakalis
Palliative Radiotherapy Vakalisfondas vakalis
 
Igrt Srt For Lung Cancer
Igrt Srt For Lung CancerIgrt Srt For Lung Cancer
Igrt Srt For Lung Cancerfondas vakalis
 
Spinal cord compression bhf aos study day mar 2014 final
Spinal cord compression bhf  aos study day mar 2014 finalSpinal cord compression bhf  aos study day mar 2014 final
Spinal cord compression bhf aos study day mar 2014 finalfondas vakalis
 
sbrt for inoperable lung cancer
sbrt for inoperable lung cancersbrt for inoperable lung cancer
sbrt for inoperable lung cancerfondas vakalis
 
Esophageal squamous Cancer-therapy-Vakalis
Esophageal squamous Cancer-therapy-VakalisEsophageal squamous Cancer-therapy-Vakalis
Esophageal squamous Cancer-therapy-Vakalisfondas vakalis
 
2o MedTech Conference, Γεώργιος Πισσάκας
2o MedTech Conference, Γεώργιος Πισσάκας2o MedTech Conference, Γεώργιος Πισσάκας
2o MedTech Conference, Γεώργιος ΠισσάκαςStarttech Ventures
 
2o MedTech Conference, Αθανάσιος Πετμεζάς
2o MedTech Conference, Αθανάσιος Πετμεζάς2o MedTech Conference, Αθανάσιος Πετμεζάς
2o MedTech Conference, Αθανάσιος ΠετμεζάςStarttech Ventures
 
Role of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung CancerRole of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung Cancerspa718
 
Motion Management in Lung Cancer Radiotherapy
Motion Management in Lung Cancer RadiotherapyMotion Management in Lung Cancer Radiotherapy
Motion Management in Lung Cancer RadiotherapyJyotirup Goswami
 
Technical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) CancerTechnical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) Cancerspa718
 
Rectum & anal canal
Rectum & anal canalRectum & anal canal
Rectum & anal canalMehul Tandel
 
Women In Games Part One
Women In Games Part OneWomen In Games Part One
Women In Games Part Onefondas vakalis
 

Viewers also liked (20)

HER2 negative metastatic breast ca
HER2 negative metastatic breast caHER2 negative metastatic breast ca
HER2 negative metastatic breast ca
 
Rectal ca -Vakalis.X
Rectal ca -Vakalis.XRectal ca -Vakalis.X
Rectal ca -Vakalis.X
 
Palliative Radiotherapy Vakalis
Palliative Radiotherapy VakalisPalliative Radiotherapy Vakalis
Palliative Radiotherapy Vakalis
 
Igrt Srt For Lung Cancer
Igrt Srt For Lung CancerIgrt Srt For Lung Cancer
Igrt Srt For Lung Cancer
 
Spinal cord compression bhf aos study day mar 2014 final
Spinal cord compression bhf  aos study day mar 2014 finalSpinal cord compression bhf  aos study day mar 2014 final
Spinal cord compression bhf aos study day mar 2014 final
 
sbrt for inoperable lung cancer
sbrt for inoperable lung cancersbrt for inoperable lung cancer
sbrt for inoperable lung cancer
 
Esophageal squamous Cancer-therapy-Vakalis
Esophageal squamous Cancer-therapy-VakalisEsophageal squamous Cancer-therapy-Vakalis
Esophageal squamous Cancer-therapy-Vakalis
 
2o MedTech Conference, Γεώργιος Πισσάκας
2o MedTech Conference, Γεώργιος Πισσάκας2o MedTech Conference, Γεώργιος Πισσάκας
2o MedTech Conference, Γεώργιος Πισσάκας
 
2o MedTech Conference, Αθανάσιος Πετμεζάς
2o MedTech Conference, Αθανάσιος Πετμεζάς2o MedTech Conference, Αθανάσιος Πετμεζάς
2o MedTech Conference, Αθανάσιος Πετμεζάς
 
Role of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung CancerRole of Radiation Therapy for Lung Cancer
Role of Radiation Therapy for Lung Cancer
 
Radiation for Lung Cancer
Radiation for Lung CancerRadiation for Lung Cancer
Radiation for Lung Cancer
 
Motion Management in Lung Cancer Radiotherapy
Motion Management in Lung Cancer RadiotherapyMotion Management in Lung Cancer Radiotherapy
Motion Management in Lung Cancer Radiotherapy
 
Technical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) CancerTechnical Advances in radiotherapy for Lung (and liver) Cancer
Technical Advances in radiotherapy for Lung (and liver) Cancer
 
Rectum & anal canal
Rectum & anal canalRectum & anal canal
Rectum & anal canal
 
Girls On Motorcycles
Girls On MotorcyclesGirls On Motorcycles
Girls On Motorcycles
 
Future Robots
Future RobotsFuture Robots
Future Robots
 
Amazing Hq Wallpapers
Amazing Hq WallpapersAmazing Hq Wallpapers
Amazing Hq Wallpapers
 
Interior Design Ideas
Interior Design IdeasInterior Design Ideas
Interior Design Ideas
 
Tech Wallpapers
Tech WallpapersTech Wallpapers
Tech Wallpapers
 
Women In Games Part One
Women In Games Part OneWomen In Games Part One
Women In Games Part One
 

Similar to Vakalis - RT for prostate cancer

Prostate Cancer and the Role of PostOp Radiation
Prostate Cancer and the Role of PostOp RadiationProstate Cancer and the Role of PostOp Radiation
Prostate Cancer and the Role of PostOp RadiationRobert J Miller MD
 
Post Operative RT in Carcinoma prostate
Post Operative RT in Carcinoma prostatePost Operative RT in Carcinoma prostate
Post Operative RT in Carcinoma prostateSreekanth Nallam
 
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...European School of Oncology
 
Five years treatment outcomes of postoperative radiotherapy in
Five years treatment outcomes of postoperative radiotherapy inFive years treatment outcomes of postoperative radiotherapy in
Five years treatment outcomes of postoperative radiotherapy inBasalama Ali
 
DrLam HighRiskProstateCancer(Azure)
DrLam HighRiskProstateCancer(Azure)DrLam HighRiskProstateCancer(Azure)
DrLam HighRiskProstateCancer(Azure)PCRI_2012conf
 
The role of Robotic Assisted laparoscopic Prostatectomy and PLND in patients ...
The role of Robotic Assisted laparoscopic Prostatectomy and PLND in patients ...The role of Robotic Assisted laparoscopic Prostatectomy and PLND in patients ...
The role of Robotic Assisted laparoscopic Prostatectomy and PLND in patients ...DrNikhilVasdev
 
Clinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma ProstateClinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma ProstateDrAyush Garg
 
ECCLU 2011 - J.J. Battermann - Prostate cancer: All the truth about local tre...
ECCLU 2011 - J.J. Battermann - Prostate cancer: All the truth about local tre...ECCLU 2011 - J.J. Battermann - Prostate cancer: All the truth about local tre...
ECCLU 2011 - J.J. Battermann - Prostate cancer: All the truth about local tre...European School of Oncology
 
Proton Therapy Vs Imrt
Proton Therapy Vs  ImrtProton Therapy Vs  Imrt
Proton Therapy Vs Imrtfondas vakalis
 
Role of radiotherapy in prostate cancer.pptx
Role of radiotherapy in prostate cancer.pptxRole of radiotherapy in prostate cancer.pptx
Role of radiotherapy in prostate cancer.pptxAtulGupta369
 
Nuovi trattamenti locali non invasivi del carcinoma della prostata
Nuovi trattamenti locali non invasivi del carcinoma della prostataNuovi trattamenti locali non invasivi del carcinoma della prostata
Nuovi trattamenti locali non invasivi del carcinoma della prostatadott. Comeri Giancarlo
 
Advances in oncological PET/CT Imaging
Advances in oncological PET/CT ImagingAdvances in oncological PET/CT Imaging
Advances in oncological PET/CT ImagingHussein Farghaly
 
Medical Students 2011 - G. Pentheroudakis - UROGENITAL CANCER SESSION - Prost...
Medical Students 2011 - G. Pentheroudakis - UROGENITAL CANCER SESSION - Prost...Medical Students 2011 - G. Pentheroudakis - UROGENITAL CANCER SESSION - Prost...
Medical Students 2011 - G. Pentheroudakis - UROGENITAL CANCER SESSION - Prost...European School of Oncology
 
SBRT in head and neck cancer
SBRT in  head and neck cancerSBRT in  head and neck cancer
SBRT in head and neck cancerDr Rushi Panchal
 
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)bkling
 

Similar to Vakalis - RT for prostate cancer (20)

Prostate Cancer and the Role of PostOp Radiation
Prostate Cancer and the Role of PostOp RadiationProstate Cancer and the Role of PostOp Radiation
Prostate Cancer and the Role of PostOp Radiation
 
Nets 2008 Carlos F Pinto
Nets 2008 Carlos F PintoNets 2008 Carlos F Pinto
Nets 2008 Carlos F Pinto
 
Post Operative RT in Carcinoma prostate
Post Operative RT in Carcinoma prostatePost Operative RT in Carcinoma prostate
Post Operative RT in Carcinoma prostate
 
7 capdevila
7 capdevila7 capdevila
7 capdevila
 
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
 
Five years treatment outcomes of postoperative radiotherapy in
Five years treatment outcomes of postoperative radiotherapy inFive years treatment outcomes of postoperative radiotherapy in
Five years treatment outcomes of postoperative radiotherapy in
 
DrLam HighRiskProstateCancer(Azure)
DrLam HighRiskProstateCancer(Azure)DrLam HighRiskProstateCancer(Azure)
DrLam HighRiskProstateCancer(Azure)
 
Prostate cancer
Prostate cancer Prostate cancer
Prostate cancer
 
The role of Robotic Assisted laparoscopic Prostatectomy and PLND in patients ...
The role of Robotic Assisted laparoscopic Prostatectomy and PLND in patients ...The role of Robotic Assisted laparoscopic Prostatectomy and PLND in patients ...
The role of Robotic Assisted laparoscopic Prostatectomy and PLND in patients ...
 
Prostate cancer
Prostate cancer   Prostate cancer
Prostate cancer
 
Pazopanib.palette.psices
Pazopanib.palette.psicesPazopanib.palette.psices
Pazopanib.palette.psices
 
Clinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma ProstateClinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma Prostate
 
ECCLU 2011 - J.J. Battermann - Prostate cancer: All the truth about local tre...
ECCLU 2011 - J.J. Battermann - Prostate cancer: All the truth about local tre...ECCLU 2011 - J.J. Battermann - Prostate cancer: All the truth about local tre...
ECCLU 2011 - J.J. Battermann - Prostate cancer: All the truth about local tre...
 
Proton Therapy Vs Imrt
Proton Therapy Vs  ImrtProton Therapy Vs  Imrt
Proton Therapy Vs Imrt
 
Role of radiotherapy in prostate cancer.pptx
Role of radiotherapy in prostate cancer.pptxRole of radiotherapy in prostate cancer.pptx
Role of radiotherapy in prostate cancer.pptx
 
Nuovi trattamenti locali non invasivi del carcinoma della prostata
Nuovi trattamenti locali non invasivi del carcinoma della prostataNuovi trattamenti locali non invasivi del carcinoma della prostata
Nuovi trattamenti locali non invasivi del carcinoma della prostata
 
Advances in oncological PET/CT Imaging
Advances in oncological PET/CT ImagingAdvances in oncological PET/CT Imaging
Advances in oncological PET/CT Imaging
 
Medical Students 2011 - G. Pentheroudakis - UROGENITAL CANCER SESSION - Prost...
Medical Students 2011 - G. Pentheroudakis - UROGENITAL CANCER SESSION - Prost...Medical Students 2011 - G. Pentheroudakis - UROGENITAL CANCER SESSION - Prost...
Medical Students 2011 - G. Pentheroudakis - UROGENITAL CANCER SESSION - Prost...
 
SBRT in head and neck cancer
SBRT in  head and neck cancerSBRT in  head and neck cancer
SBRT in head and neck cancer
 
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)
 

More from fondas vakalis

Her2 positive metastatic breast ca
Her2 positive metastatic breast caHer2 positive metastatic breast ca
Her2 positive metastatic breast cafondas vakalis
 
Advanced breast cancer
Advanced breast cancerAdvanced breast cancer
Advanced breast cancerfondas vakalis
 
Radiobiology behind dose fractionation
Radiobiology behind dose fractionationRadiobiology behind dose fractionation
Radiobiology behind dose fractionationfondas vakalis
 
Vakalis - gastric ca radiotherapy
Vakalis - gastric ca radiotherapyVakalis - gastric ca radiotherapy
Vakalis - gastric ca radiotherapyfondas vakalis
 
testicular cancer and radiotherapy
testicular cancer and radiotherapytesticular cancer and radiotherapy
testicular cancer and radiotherapyfondas vakalis
 
Vakalis new techniques in breast radiotherapy
Vakalis new techniques in breast radiotherapyVakalis new techniques in breast radiotherapy
Vakalis new techniques in breast radiotherapyfondas vakalis
 
Femmes soldats dans_le_monde
Femmes soldats dans_le_mondeFemmes soldats dans_le_monde
Femmes soldats dans_le_mondefondas vakalis
 
New techniques in breast radiotherapy
New techniques in breast radiotherapyNew techniques in breast radiotherapy
New techniques in breast radiotherapyfondas vakalis
 
Adaptive Radiation Therapy With Tomo Therapy
Adaptive Radiation Therapy With Tomo TherapyAdaptive Radiation Therapy With Tomo Therapy
Adaptive Radiation Therapy With Tomo Therapyfondas vakalis
 
Accidents In Radiation Therapy
Accidents In Radiation TherapyAccidents In Radiation Therapy
Accidents In Radiation Therapyfondas vakalis
 

More from fondas vakalis (19)

Her2 positive metastatic breast ca
Her2 positive metastatic breast caHer2 positive metastatic breast ca
Her2 positive metastatic breast ca
 
nonsquamous NSCLC
nonsquamous NSCLCnonsquamous NSCLC
nonsquamous NSCLC
 
Advanced breast cancer
Advanced breast cancerAdvanced breast cancer
Advanced breast cancer
 
Vegf in colorectal ca
Vegf in colorectal caVegf in colorectal ca
Vegf in colorectal ca
 
817731 slides
817731 slides817731 slides
817731 slides
 
Radiobiology behind dose fractionation
Radiobiology behind dose fractionationRadiobiology behind dose fractionation
Radiobiology behind dose fractionation
 
Vakalis - gastric ca radiotherapy
Vakalis - gastric ca radiotherapyVakalis - gastric ca radiotherapy
Vakalis - gastric ca radiotherapy
 
Vakalis.X H&N CANCER
Vakalis.X  H&N CANCERVakalis.X  H&N CANCER
Vakalis.X H&N CANCER
 
Vakalis pancreas
Vakalis pancreasVakalis pancreas
Vakalis pancreas
 
Vakalis prostate
Vakalis prostateVakalis prostate
Vakalis prostate
 
testicular cancer and radiotherapy
testicular cancer and radiotherapytesticular cancer and radiotherapy
testicular cancer and radiotherapy
 
Vakalis new techniques in breast radiotherapy
Vakalis new techniques in breast radiotherapyVakalis new techniques in breast radiotherapy
Vakalis new techniques in breast radiotherapy
 
Femmes soldats dans_le_monde
Femmes soldats dans_le_mondeFemmes soldats dans_le_monde
Femmes soldats dans_le_monde
 
Anal ca vakalis
Anal  ca vakalisAnal  ca vakalis
Anal ca vakalis
 
New techniques in breast radiotherapy
New techniques in breast radiotherapyNew techniques in breast radiotherapy
New techniques in breast radiotherapy
 
Iort
IortIort
Iort
 
Neurotoxicity
NeurotoxicityNeurotoxicity
Neurotoxicity
 
Adaptive Radiation Therapy With Tomo Therapy
Adaptive Radiation Therapy With Tomo TherapyAdaptive Radiation Therapy With Tomo Therapy
Adaptive Radiation Therapy With Tomo Therapy
 
Accidents In Radiation Therapy
Accidents In Radiation TherapyAccidents In Radiation Therapy
Accidents In Radiation Therapy
 

Recently uploaded

Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)1922Jaygohel
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfrg0000009
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint HealthArthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint HealthGokuldas Hospital
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Forensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationForensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationKavitha Krishnan
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 

Recently uploaded (20)

Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdf
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint HealthArthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Forensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationForensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentation
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 

Vakalis - RT for prostate cancer

  • 1. Ε. ΑΝΔΡΙΩΤΗΣ Νεώτερα δεδομζνα ςτην ακτινοθεραπεία του καρκίνου του προςτάτη 2ο Συμπόσιο Κλινικής Ογκολογίας Ρόδου Ακτινοθεραπευτήσ Ογκολόγοσ Euromedica – Αθήναιον Α & Ιατρικό Κζντρο Αθηνών
  • 5. Male Cancer Mortality Rates 1930 to 2009 prostate colorectal stomach lung
  • 6. CaPSURE: Risk Category at Diagnosis 0 20 40 60 80 100 1989 1990 1991 1992 1993 1994 1995 1996 1997 1999 2000 2001 2002 Patients(%) High risk Intermediate risk Low risk 30.2% 37.3% 32.5% 25.1% 38.5% 36.4% 16.0% 37.2% 46.8% 36.6% 33.8% 29.5% Reprinted with permission from Cooperberg MR et al. J Urol. 2003;170:S21
  • 8. Καηεςθύνζειρ για ηην θεπαπεία ηοπικήρ νόζος Ιαηπικά πποβλήμαηα αζθενούρ Νοζηπόηηηα Ca πποζηάηος Πποζδόκιμο επιβίυζηρ (αναμενόμενη) • Δνδοκατική νόζορ (Σ1/Σ2), Gleason score (< 7) & PSA(<10) - Ρηδηθή πξνζηαηεθηνκή ή αθηηλνζεξαπεία ή παξαθνινύζεζε • Σοπικά πποσυπημένη νόζορ (Σ3/Σ4) – Αθηηλνζεξαπεία + Οξκνληθόο απνθιεηζκόο (LHRH αλάινγα)
  • 9. bRFS in pts with favorable tumors (T1-T2A, bGS< 6, iPSA< 10 ng/ml) Kupelian PA, JCO 2002
  • 10. bRFS in pts with unfavorable tumors (T2b-T2c, bGS> 6, iPSA>10 ng/ml) Kupelian PA, JCO 2002
  • 11. Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer The Prostate Cancer Outcomes Study (PCOS), comprised 1655 men in whom localized prostate cancer had been diagnosed between the ages of 55 and 74 years and who had undergone either surgery (1164 men) or radiotherapy (491 men). Functional status was assessed at baseline and at 2, 5, and 15 years after diagnosis • Urinary Incontinence: worse with surgery at 2 and 5 years but the same by 15 years • Erectile Dysfunction: worse with surgery at 2 and 5 years but the same by 15 years • Bowel Urgency: worse with radiation at 2 and 5 years' but by 15 years' the same N Engl J Med 2013; 368:436-445
  • 13. ΝΑΙ ! Η ΑΚΘ βειηηώλεη ηελ 10-εηή επηβίσζε Warde P et all Lancet 2011 Widmark A et all Lancet 2009
  • 20. ΣΟΠΙΚΗ ΤΠΟΣΡΟΠΗ – ΓΟ΢Η ΑΚΣΙΝΟΘΔΡΑΠΔΙΑ΢
  • 24. Σςσαιοποιημένερ μελέηερ πος δείσνοςν ηο όθελορ από ηην αύξηζη ηηρ δόζηρ (συπίρ IMRT και οπμονοθεπαπεία) RCT N Comparison Result Pollack (MDA) 2007 update 301 70Gy/35 vs. 78Gy/39 59% vs. 78% bPFS at 5 years Zietman 2005 393 70.2Gy vs. 79.2Gy (proton boost) 61% vs. 80% bPFS at 5 years Peeters (Dutch) 2006 664 68Gy/34 vs. 78Gy/39 54% vs. 64% FFF at 5 years Dearnaley (RTO1) 2007 843 64Gy/32 vs. 74Gy/37 60% vs. 71% bPFS at 5 years Hoskin (Mt Vernon) 2007 220 55Gy/20 vs. 35.75Gy/13 + HDR 8.5Gy x 2 64% vs. 80% bPFS at 5 years bPFS=biochemical progression free survival FFF= freedom from failure
  • 25. Low Risk T1-2, GS ≤6, PSA ≤10 Memorial Sloan Kettering Cancer Center IMRT Dose Escalation Zelefsky MJ, Chan H, et. Al. Journal of Urology Vol. 176, 1415-1419, Oct 2006
  • 26. Intermediate Risk Memorial Sloan Kettering Cancer Center IMRT Dose Escalation Zelefsky MJ, Chan H, et. Al. Journal of Urology Vol. 176, 1415-1419, Oct 2006 T1-2, GS 6, PSA > 10 T1-2, GS >6, PSA  10 T3, GS  6, PSA  10
  • 27. High Risk GS >6, PSA >10 Memorial Sloan Kettering Cancer Center IMRT Dose Escalation Zelefsky MJ, Chan H, et. Al. Journal of Urology Vol. 176, 1415-1419, Oct 2006
  • 28. Improving the Results of Radiotherapy Dose escalation– increasing the dose of radiation by 10% can increase local control by 20% (level 1 evidence) 3D Conformal, IMRT, HDR Brachytherapy boost Combination treatment with radiotherapy and androgen suppression
  • 30. Αύξηζη ηηρ δόζηρ – Σοξικόηηηα
  • 31. Απώηεπη Σοξικόηηηα ζηιρ μεγάλερ μη- IMRT μελέηερ αύξηζηρ ηηρ δόζηρ Γαζηπενηεπική Σοξικόηηηα Σοξικόηηηα από Οςποποιηηικό Grade 2 Grade 3 Grade 2 Grade 3 Κλαζζική Γόζη 8 – 23% 1 – 2% 6 – 28% 1 – 8% Ττηλή Γόζη (Μη-IMRT) 7 – 30% 1 -7% 10 – 30% 1 – 15 % 2 θοπέρ μεγαλύηεπορ κίνδςνορ ζοβαπήρ ηοξικόηηηαρ !
  • 37. J Urol 2001; 166: 876 ≥ Grade 2 Απώηεξε Σνμηθόηεηα από Οξζό 3D-CRT: 14% IMRT: 2% p= 0.005
  • 38. Γαζηπενηεπική Σοξικόηηηα Σοξικόηηηα Οςποποιηηικού Grade 2 Grade 3 Grade 2 Grade 3 Κλαζζική Γόζη 8 – 23% 1 – 2% 6 – 28% 1 – 8% Ττηλή Γόζη (Μη-IMRT) 7 – 30% 1 -7% 10 – 30% 1 – 15 % Ττηλή Γόζη (IMRT) 1 – 2% 0 – 3% 9 – 23% 0 – 6% Απώηεπη Σοξικόηηηα ζηιρ IMRT μελέηερ αύξηζηρ ηηρ δόζηρ Κίνδςνορ ζοβαπήρ ηοξικόηηηαρ Υαμηλή δόζη συπίρ IMRT = Ττηλή δόζη με IMRT
  • 45. Μέηπια Τποκλαζμαηοποίηζη 8 εβδομάδερ θεπαπείαρ είναι απαπαίηηηερ; Οι κλινικέρ μελέηερ
  • 48. • Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer • Hypothesis: hypofractionated radiotherapy schedules for localised prostate cancer will improve the therapeutic ratio by either: a) Improving tumour control b) Reducing normal tissue side effects CHHiP Trial
  • 49. T1B - T3A N0 M0 Estimated Risk of SV involvement ≤ 30% PSA ≤ 30ng/ml Randomise Group 1 74Gy / 37F 7.5 weeks (Standard) Group 2 60Gy / 20F 4.0 weeks (Hypofractionation) Group 3 57Gy / 19F 3.8 weeks (Hypofractionation) Trial Schema CHHiP Trial
  • 50. T1c-2a GS <7 PSA <10 73.8 Gy/41 Fx 70 Gy/28 Fx RTOG 0415 Schema n=800 Endpoint is 5 Year BFFF Non-inferiority margin 7% (Control 85%, Exp 78%)
  • 55. SBRT cheaper but more toxic than IMRT for Prostate Cancer The study results were published online March 10 in theJournal of Clinical Oncology.
  • 58. CT scan is obtained at the time of the Simulation Fiducials may be inserted before this step. CT images are then imported into the treatment planning computer
  • 59. bladder Radiation zone prostate rectum Goal = radiation zone precisely around the prostate cancer with small margin
  • 60. IMRT (intensity modulated radiation therapy) using 7 different beams to target the prostate The computer can determine the optimal number of beams to deliver the radiation dose to hit the target and avoid other structures
  • 61. Prostate Seminal Vesicles Courtesy: Chester Ramsey Prostate Seminal Vesicles Alignment on markers Alignment on mid gland prostate Κίνηςη του προςτάτη
  • 62. AP  4.15 mm SI  3.14 mm RL  1.92 mm
  • 63. There is significant movement of the prostate gland based on daily gas in rectum Planned target Rectal gas No Rectal gas Planned target, missed badly if rectal gas pushes the prostate forward
  • 65. After IMRT was established then IGRT (image guided) was introduced
  • 67. Lower Risk of Side Effects with Image Guided IMRT compared to IMRT
  • 68. Is there ever a need for radiation after a man has already had his prostate removed PostOp Radiation (Adjuvant Therapy) if the pathology report from the surgery raises the concern: “was the cancer completely removed?” Salvage Radiation
  • 69. Οπιζμοί • Άκεζα κεηεγρεηξεηηθή (adjuvant) – Με αληρλεύζηκν PSA κεηεγρεηξεηηθά – Α/ζ ζε 3-12 κήλεο (αθνύ βειηησζεί ε αθξάηεηα) • Αθηηλνζεξαπεία δηάζσζεο (salvage) – Αληρλεύζηκν PSA κεηεγρεηξεηηθά – ↑ ηνπ PSA αθνύ πξώηα κεδεληζηεί
  • 70. NCCN Advice on PostOp Radiation RP (radical prostatectomy) PLND (pelvic lymph node dissection) RT (radiation therapy) ADT (androgen deprivation therapy e.g. Lupron)
  • 71. Adverse Features 1.Positive Surgical Margins 2.Invasion into the Seminal Vesicles 3.Extracapsular Extension 4.Detectable PSA (after surgery the PSA should fall to undetectable by a few weeks)
  • 72. Impact of Path Reporting Positive Surgical Margins Risk Group + Margins - Margins Low risk 5.1% 0.4% Intermediate 17% 6.5% High 43% 21.5% Odds of a PSA Relapse J Urol. 2010;183(1):145.
  • 73. PostOp Radiation…does it work? SWOG 8794 Trial path (425 men) = extraprostatic extension after surgery 10 Year PSA Cure Rate (seminal vesicle) Surgery Only 12% Surgery Plus Radiation 36% EORTC (1005 men) 5 Year Cure Rate if Positive Margins Surgery Only 49% Surgery Plus Radiation 78% German Study (Wiegel, 268 men) 5 Year Cure Rate all T3 Surgery Only 54% Surgery Plus Radiation 72%
  • 74. Survival Benefits from PostOp Radiation for High Risk Patients RT RTRT No RT No RTNo RT
  • 76. Is it Better to Treat PostOp for High Risk Features or to Wait and Treat later if the PSA starts rising (salvage)? 8 Year Specific Survival by Group and Therapy Immediate RT Delayed Positive Margins 91% 67% Extra-capsular Spread 92% 75% Gleason 7 88% 72% Node Metastases 88% 68% Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients Cozzarini. IJROBP 2004;59:674
  • 77. Υπόνορ έναπξηρ ηηρ άμεζηρ α/θ ≥ 3 επειζόδια ακράηειας : ζηοσς 6 μήνες: 33%, ζηοσς 12 μήνες: 18%, ζηοσς 24-60 μήνες: 15% ΢ηα πεξηζζόηεξα θέληξα 3-12 κήλεο κεηεγρ/θά αθνύ απνθαηαζηαζεί ε εγθξάηεηα • Δελ θαίλεηαη λα επεξεάδεη ηελ λόζν • Η πνιύ πξώηκε έλαξμε → ↑ ηνπ % απώηεξεο ηνμηθόηεηαο από ην νπξνπνηεηηθό Feng et al, IJROBP, 2005
  • 78. Salvage Radiation: if months or years after surgery the PSA blood tests starts rising again
  • 79. Salvage Radiation…does it work? Depends… Original Pathology What was the Gleason? Where the surgical margins clear? Did the cancer involve the seminal vesicles or lymph nodes? Was there extra-capsular spread? How long ago was the surgery? How fast is the PSA rising (doubling time)? How high the did PSA get before deciding to try radiation? How high a dose of radiation will be used?
  • 83. Does Salvage Radiation Improve Survival? Mayo (2657) No improvement in 10 y mortality (70% versus 69%) Hopkins (635) Improved cancer mortality at 10 years 86% versus 62% Duke (519) All cause mortality at 11 years was reduced by 47% J Urol. 2009;182(6):2708 JAMA. 2008;299(23):2760.
  • 84. ΑΚΣΙΝΟΘΔΡΑΠΔΙΑ ΢ΣΟΝ ΠΡΩΙΜΟ ΚΑΡΚΙΝΟ ΣΟΤ ΠΡΟ΢ΣΑΣΗ • Δξυηεπική ακηινοθεπαπεία (EBRT) – ΢ύμμοπθη ηξηζδηάζηαηε αθηηλνζεξαπεία (3 Dimensional Conformal Radiotherapy – 3D CRT) – Σξηζδηάζηαηε αθηηλνζεξαπεία διαμοπθούμενηρ ένηαζηρ (Intensity Modulated Radiation Therapy – IMRT/VMAT-IGRT) – Αθηηλνζεξαπεία κε ππυηόνια (Proton Beam Radiation Therapy) – ΢ηεπεοηακηική αθηηλνζεξαπεία ηνπ πξνζηάηε (Stereotactic Radiotherapy) • Βπασςθεπαπεία – Μόληκα εκθπηεύκαηα ρακεινύ ξπζκνύ δόζεο(LDR) (seeds I-125 ή Pd-103) – Πξνζσξηλά εκθπηεύκαηα πςεινύ ξπζκνύ δόζεο (HDR) (Iridium-192 sources)
  • 86. ΔΝΓΔΙΞΔΙ΢ ΒΡΑΥΤΘΔΡΑΠΔΙΑ΢ ΣΟΤ ΠΡΟ΢ΣΑΣΗ (LDR) RECOMMENDED OPTIONAL INVESTIGATIONAL Do well Fair Do poorly PSA (ng/ml) <10 10-20 >20 Gleason Score 5-6 7 8-10 Stage T1c - T2a T2b - T2c T3 IPSS 0 - 8 9 - 19 >20 Prostate Volume (g) <40 40 - 60 >60 Q max mls/sec >15 15 - 10 <10 Residual Volume cc >200 TURP +/- + ESTRO/EAU/EORTC recommendations on seed implantation for localized prostate Cancer. Ash D et al. Radiother Oncol; 2000: 57, 315-321
  • 90. ηελεςηαίερ ζκέτειρ Εμσηεξηθή Αθηηλνζεξαπεία αζθαιήο θαη δξαζηηθή • βειηηώλεη ηελ επηβίσζε κε απνδεθηή ηνμηθόηεηα ζε πςεινύ θηλδύλνπ θαη ηνπηθά πξνρσξεκέλν Ca • αύμεζε ηεο δόζεο πξνθαιεί θαιύηεξν έιεγρν (level 1 evidence) Σερλνινγία πνπ δηαηίζεηαη ζηελ ΑΚΘ πνιύ πξνρσξεκέλε • απμάλεη ηε ζπλνιηθή δόζε • ρνξεγεί πςειή δόζε αλά ζπλεδξία • κεηώλεη ηνλ ζπλνιηθό ρξόλν ζεξαπείαο • παξαθνινπζεί ηε θίλεζε ηνπ πξνζηάηε θη εληνπίδεη αθξηβώο ην ζηόρν Είλαη ππεπζπλόηεηα ησλ γηαηξώλ λα γλσξίδνπλ πνηεο πεξηνρέο λα αθηηλνβνιήζνπλ, πώο λα ζρεδηάζνπλ ηε ζεξαπεία θαη πόηε πξέπεη λα αθηηλνβνιήζνπλ